Brief: Ascentage Pharma Group International Says Olverembatinib Gets Approval From NMPA
21/10/2020 16:09
Oct 21 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ANNOUNCES OLVEREMBATINIB OF GUANGZHOU HEALTHQUEST PHARMA
OBTAINED APPROVAL FROM CDE UNDER NMPA
Source text for Eikon: ID:nHKS7SH3Hr
Further company coverage: 6855.HK
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up